Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial

Single Dose ◽

Insulin Glargine ◽

Phase I ◽

Randomized Trial ◽

Fixed Ratio ◽

Japanese Patients

Effect of Single Dose of Insulin Glargine/Lixisenatide Fixed-Ratio Combination (IGlarLixi) on Postprandial Glucodynamic Response in Japanese Patients with Type 2 Diabetes Mellitus

Diabetes ◽

10.2337/db18-1075-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 1075-P

Author(s):

MEGUMI INOUE ◽

MARTIN LORENZ ◽

HIDEYA MUTO ◽

YASUHIRO HASHIMOTO

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Single Dose ◽

Insulin Glargine ◽

Fixed Ratio ◽

Japanese Patients

Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP‐L randomized clinical trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14005 ◽

2020 ◽

Vol 22 (S4) ◽

pp. 3-13 ◽

Cited By ~ 3

Author(s):

Hideaki Kaneto ◽

Akane Takami ◽

Robert Spranger ◽

Atsushi Amano ◽

Daisuke Watanabe ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Clinical Trial ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Decision letter for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v3/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Decision letter for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v2/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Review for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v1/review1 ◽

2019 ◽

Author(s):

Graydon Meneilly

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Decision letter for "Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP‐L Randomized Clinical Trial"

10.1111/dom.14005/v1/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Clinical Trial ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Author response for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v3/response1 ◽

2020 ◽

Author(s):

Yasuo Terauchi ◽

Takahiro Nakama ◽

Robert Spranger ◽

Atsushi Amano ◽

Takahiro Inoue ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Review for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v2/review2 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Review for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v1/review2 ◽

2019 ◽

Author(s):

Michael E. Trautmann

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Author response for "Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP‐L Randomized Clinical Trial"

10.1111/dom.14005/v2/response1 ◽

2020 ◽

Author(s):

Hideaki Kaneto ◽

Akane Takami ◽

Robert Spranger ◽

Atsushi Amano ◽

Daisuke Watanabe ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Clinical Trial ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽